top of page

Could GLP-1 receptor agonist Increase Risk of Eye Disease?

A recent study published in JAMA Ophthalmology suggests a potential risk associated with the widely used GLP-1 receptor agonist, semaglutide. This groundbreaking research could be the first to report an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients using semaglutide for type 2 diabetes or weight management.

Key Findings:

  • Participants: 16,827 patients, making it a substantial and robust study.

  • Patients with type 2 diabetes prescribed semaglutide had a higher incidence of NAION (8.9% vs. 1.8%) compared to those on non-GLP-1 RA medications.

  • Overweight or obese patients on semaglutide also showed a higher incidence of NAION (6.7% vs. 0.8%).

These results highlight the importance of monitoring eye health for patients on semaglutide. Further research is needed to confirm these findings and assess causality.


Hathaway, J.T., et al., Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology, 2024.

2 views0 comments


bottom of page